Neamati N - Search Results

1

Role of the ERO1-PDI interaction in oxidative protein folding and disease.

Shergalis AG, Hu S, Bankhead A 3rd, Neamati N. Shergalis AG, et al. Among authors: neamati n. Pharmacol Ther. 2020 Jun;210:107525. doi: 10.1016/j.pharmthera.2020.107525. Epub 2020 Mar 20. Pharmacol Ther. 2020. PMID: 32201313 Free PMC article. Review.

2

Protein disulfide isomerase: a promising target for cancer therapy.

Xu S, Sankar S, Neamati N. Xu S, et al. Among authors: neamati n. Drug Discov Today. 2014 Mar;19(3):222-40. doi: 10.1016/j.drudis.2013.10.017. Epub 2013 Oct 31. Drug Discov Today. 2014. PMID: 24184531 Review.

3

Discovery and Mechanistic Elucidation of a Class of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma.

Kyani A, Tamura S, Yang S, Shergalis A, Samanta S, Kuang Y, Ljungman M, Neamati N. Kyani A, et al. Among authors: neamati n. ChemMedChem. 2018 Jan 22;13(2):164-177. doi: 10.1002/cmdc.201700629. Epub 2018 Jan 4. ChemMedChem. 2018. PMID: 29235250 Free PMC article.

4

Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.

Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A 3rd, Broses LJ, Lorenzatti Hiles G, Liebert M, Rubin JR, Day KC, Hussain M, Neamati N, Tomlins S, Palmbos PL, Grivas P, Day ML. Tamura S, et al. Among authors: neamati n. Bladder Cancer. 2018 Jan 20;4(1):77-90. doi: 10.3233/BLC-170144. Bladder Cancer. 2018. PMID: 29430509 Free PMC article.

5

Current Challenges and Opportunities in Treating Glioblastoma.

Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N. Shergalis A, et al. Among authors: neamati n. Pharmacol Rev. 2018 Jul;70(3):412-445. doi: 10.1124/pr.117.014944. Pharmacol Rev. 2018. PMID: 29669750 Free PMC article.

6

Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.

Hu S, Jin Y, Liu Y, Ljungman M, Neamati N. Hu S, et al. Among authors: neamati n. Eur J Med Chem. 2018 Oct 5;158:884-895. doi: 10.1016/j.ejmech.2018.09.037. Epub 2018 Sep 15. Eur J Med Chem. 2018. PMID: 30253345 Free PMC article.

7

Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.

Madak JT, Bankhead A 3rd, Cuthbertson CR, Showalter HD, Neamati N. Madak JT, et al. Among authors: neamati n. Pharmacol Ther. 2019 Mar;195:111-131. doi: 10.1016/j.pharmthera.2018.10.012. Epub 2018 Oct 19. Pharmacol Ther. 2019. PMID: 30347213 Review.

8

TAIJI: approaching experimental replicates-level accuracy for drug synergy prediction.

Li H, Hu S, Neamati N, Guan Y. Li H, et al. Among authors: neamati n. Bioinformatics. 2019 Jul 1;35(13):2338-2339. doi: 10.1093/bioinformatics/bty955. Bioinformatics. 2019. PMID: 30462169

9

Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors.

Yang S, Shergalis A, Lu D, Kyani A, Liu Z, Ljungman M, Neamati N. Yang S, et al. Among authors: neamati n. J Med Chem. 2019 Apr 11;62(7):3447-3474. doi: 10.1021/acs.jmedchem.8b01951. Epub 2019 Apr 2. J Med Chem. 2019. PMID: 30759340 Free PMC article.

10

Metal-Free C-2-H Alkylation of Quinazolin-4-ones with Alkanes via Cross-Dehydrogenative Coupling.

Mao S, Luo K, Wang L, Zhao HY, Shergalis A, Xin M, Neamati N, Jin Y, Zhang SQ. Mao S, et al. Among authors: neamati n. Org Lett. 2019 Apr 5;21(7):2365-2368. doi: 10.1021/acs.orglett.9b00638. Epub 2019 Mar 25. Org Lett. 2019. PMID: 30907598

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

284 results

Search Page